Annual General Meeting held on May 13, 2025 - Poll Results
Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, May 13, 2025: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM; HKEX:13) today announces that all ordinary resolutions and special resolution put to its Annual General Meeting ("AGM") held on May 13, 2025 were duly passed. The poll results of the resolutions were as follows:
|
Ordinary Resolutions | Number of Votes (%)* |
Passed by Shareholders | |||
|
For
|
Against
|
Withheld# | |||
| 1. | To consider and adopt the audited Financial Statements, and the Reports of the Directors and the Independent Auditors for the year ended December 31, 2024.
| 493,635,784 (99.9863%) | 67,770 (0.0137%) | 54,915
| Yes |
| 2(A). | To re-elect Dr Dan ELDAR as a Director.
| 479,808,571 (97.1824%) | 13,910,941 (2.8176%) | 38,955 | Yes |
| 2(B). | To re-elect Dr Weiguo SU as a Director.
| 481,283,821 (97.4806%) | 12,438,811 (2.5194%) | 35,835 | Yes |
| 2(C). | To re-elect Mr CHENG Chig Fung, Johnny as a Director.
| 481,167,431 (97.4570%)
| 12,555,206 (2.5430%) | 35,830 | Yes |
| 2(D). | To re-elect Ms Edith SHIH as a Director.
| 466,597,573 (94.5061%) | 27,124,459 (5.4939%) | 35,935 | Yes |
| 2(E). | To re-elect Ms Ling YANG as a Director.
| 484,362,585 (98.1042%) | 9,360,052 (1.8958%) | 35,830 | Yes |
| 2(F). | To re-elect Dr Renu BHATIA as a Director. | 493,441,294 (99.9430%)
| 281,240 (0.0570%) | 35,935 | Yes |
| 2(G). | To re-elect Dr Chaohong HU as a Director.
| 493,441,904 (99.9431%) | 280,740 (0.0569%) | 35,825 | Yes |
| 2(H). | To re-elect Professor MOK Shu Kam, Tony as a Director.
| 492,694,533 (99.7918%) | 1,028,006 (0.2082%) | 35,930 | Yes |
| 2(I). | To re-elect Mr WONG Tak Wai as a Director.
| 493,633,871 (99.9820%)
| 88,768 (0.0180%) | 35,830 | Yes |
| 3. | To re-appoint PricewaterhouseCoopers and PricewaterhouseCoopers Zhong Tian LLP as the Auditors of the Company for Hong Kong financial reporting and US financial reporting purposes, respectively, and to authorize the Directors to fix the Auditors' remuneration.
| 492,729,314 (99.8004%) | 985,390 (0.1996%) | 43,765 | Yes |
| Special Resolution | |||||
| 4.
| To grant a general mandate to the Directors to issue additional shares of the Company.^
| 493,550,312 (99.9637%) | 179,327 (0.0363%) | 28,830 | Yes |
| Ordinary Resolution | |||||
| 5. | To grant a general mandate to the Directors to repurchase shares of the Company.^
| 493,321,158 (99.9180%) | 405,036 (0.0820%) | 32,275 | Yes |
* Percentages rounded to 4 decimal places.
# A vote withheld is not a vote in law and is not counted in the calculation of the proportion of the votes for or against a resolution.
^ The full text of Resolutions 4 and 5 are set out in the notice of AGM dated April 8, 2025.
Notes:
(1) All directors of the Company, namely Dr Dan ELDAR, Dr Weiguo SU, Mr CHENG Chig Fung, Johnny, Ms Edith SHIH, Ms Ling YANG, Mr Paul Rutherford CARTER, Dr Renu BHATIA, Dr Chaohong HU, Mr Graeme Allan JACK, Professor MOK Shu Kam, Tony and Mr WONG Tak Wai, attended the AGM, either in person or by means of electronic facilities.
(2) Number of shares entitling the holders to attend and vote on the resolution at the AGM: 871,601,095 shares.
(3) Number of shares entitling the holders to attend and abstain from voting in favor as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") at the AGM: Nil.
(4) Number of shares for holders required under the Listing Rules to abstain from voting at the AGM: Nil.
(5) The scrutineer for the poll at the AGM was Computershare Investor Services (Jersey) Limited, the Principal Share Registrar of the Company.
About HUTCHMED
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. Іt is committed to the discovery, global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, and the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn.
CONTACTS
| Investor Enquiries
| +852 2121 8200 / ir@hutch-med.com |
| Media Enquiries | |
| FTI Consulting - | +44 20 3727 1030 / HUTCHMED@fticonsulting.com |
| Ben Atwell / Alex Shaw | +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) |
| Brunswick - Zhou Yi | +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
|
| Panmure Liberum | Nominated Advisor and Joint Broker |
| Atholl Tweedie / Freddy Crossley / Rupert Dearden | +44 20 7886 2500 |
| | |
| HSBC | Joint Broker |
| Simon Alexander / Alina Vaskina / Arnav Kapoor
| +44 20 7991 8888 |
| Cavendish | Joint Broker |
| Geoff Nash / Nigel Birks | +44 20 7220 0500 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.